Press Release
Ability Pharmaceuticals launches a new updated website with a fresh design
February 20, 2017
Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced the launch of its new web site (www.abilitypharma.com)
The site includes extensive and updated information to provide a detailed overview of the company, its products under development and ongoing projects. It will also help visitors stay informed with the latest news of the company, their publications and the attending events, specifically featured in the “Media Center” section.
Visitors can now benefit from a contemporary design and a richer online content that is easier to navigate. Moreover, the new website has been created with the user experience firmly in mind, and it has been designed using the latest technology so the site is compatible with today's browsers and mobile devices without the need for Adobe Flash to view it.
“I can’t tell you how excited we are about this new website. AbilityPharma has really grown and matured in the last year and we needed a website that truly reflected who we’ve became,” said Carles Domènech, Chief Executive Officer and co-founder of AbilityPharma.
About Ability Pharmaceuticals
AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. Established in 2009 and with one product, ABTL0812, an oral autophagy targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC, is positioning itself as one of the fast growers in the Catalan and Spanish biotech sector.
In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals, Inc. to develop and market the product in Greater China.
Ability Pharmaceuticals has headquarters in Cerdanyola del Vallès (Barcelona, Catalonia, Spain) at Parc Tecnològic del Vallès and Parc de Recerca UAB. Current shareholders include the biotech venture firms Inveready and SODENA, its founders and private investors, and has the financial support from ACCIO (Government of Catalonia), CDTI, ENISA and MINECO (Government of Spain).
The site includes extensive and updated information to provide a detailed overview of the company, its products under development and ongoing projects. It will also help visitors stay informed with the latest news of the company, their publications and the attending events, specifically featured in the “Media Center” section.
Visitors can now benefit from a contemporary design and a richer online content that is easier to navigate. Moreover, the new website has been created with the user experience firmly in mind, and it has been designed using the latest technology so the site is compatible with today's browsers and mobile devices without the need for Adobe Flash to view it.
“I can’t tell you how excited we are about this new website. AbilityPharma has really grown and matured in the last year and we needed a website that truly reflected who we’ve became,” said Carles Domènech, Chief Executive Officer and co-founder of AbilityPharma.
About Ability Pharmaceuticals
AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. Established in 2009 and with one product, ABTL0812, an oral autophagy targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC, is positioning itself as one of the fast growers in the Catalan and Spanish biotech sector.
In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals, Inc. to develop and market the product in Greater China.
Ability Pharmaceuticals has headquarters in Cerdanyola del Vallès (Barcelona, Catalonia, Spain) at Parc Tecnològic del Vallès and Parc de Recerca UAB. Current shareholders include the biotech venture firms Inveready and SODENA, its founders and private investors, and has the financial support from ACCIO (Government of Catalonia), CDTI, ENISA and MINECO (Government of Spain).
LATEST NEWS
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
